Amazon Launches $5-a-Month Prescription Drug Plan in Further Healthcare Push

The new Prime membership benefit, dubbed RxPass, will offer unlimited access to commonly prescribed generic medications. Read More...


Eli Lilly to invest $450 million more to expand diabetes drug plant capacity

The company has been struggling to meet high demand for the drugs Trulicity and Mounjaro, especially due to production of multiple dosage forms for each of them. The company already had plans to double the production capacity this year for incretins, the class of diabetes drugs to which Trulicity and Mounjaro belong. “We’re on track to achieve the goal we shared in November 2022 of doubling incretin capacity by the end of this year, but this investment is key to ensuring even more patients will have access to medicines they need in the future,” Edgardo Hernandez, president of Lilly’s manufacturing operations, said in a statement.

Read More

Add Comment

Click here to post a comment